|
gptkbp:instanceOf
|
gptkb:vaccine
|
|
gptkbp:age
|
adults 18 years and older
|
|
gptkbp:alsoKnownAs
|
gptkb:NVX-CoV2373
|
|
gptkbp:approvedBy
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:South_Korea
gptkb:United_Kingdom
gptkb:United_States
December 2021
|
|
gptkbp:boosterRecommended
|
yes
|
|
gptkbp:category
|
gptkb:COVID-19
gptkb:vaccine
gptkb:protein_subunit_vaccine
|
|
gptkbp:contains
|
recombinant spike protein
saponin-based adjuvant
|
|
gptkbp:containsAdjuvant
|
gptkb:Matrix-M
|
|
gptkbp:developedBy
|
gptkb:Novavax
|
|
gptkbp:dosingSchedule
|
two doses, 3 weeks apart
|
|
gptkbp:efficacyAgainstSymptomaticCOVID19
|
~90%
|
|
gptkbp:emergencyServices
|
gptkb:World_Health_Organization
|
|
gptkbp:indication
|
prevention of COVID-19
|
|
gptkbp:marketedAs
|
gptkb:Serum_Institute_of_India_(as_Covovax)
gptkb:Takeda_(in_Japan)
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
nausea
fatigue
headache
joint pain
muscle pain
injection site pain
|
|
gptkbp:storage
|
2–8°C
liquid suspension
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
gptkb:protein_subunit_vaccine
|
|
gptkbp:WHOStatus
|
gptkb:EUL_(Emergency_Use_Listing)
|
|
gptkbp:bfsParent
|
gptkb:Novavax
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nuvaxovid
|